Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 34

Sort by

Sort Order Select

Journal Articles

Serum Cell-Free DNA Concentration Is Predictive of Survival Outcomes and Its Genetic Mutation Analysis May Be Viable in Obtaining Pathological Information

Yuko Shirouchi, MD, Yuko Mishima, MD PhD, Yuji Mishima, PhD, Masahiro Yokoyama, MD, Noriko Nishimura, MD PhD, Yoshiharu Kusano, MD, Hideki Uryu, MD, Takashi Okabe, MD, Norihito Inoue, MD, Takanori Fukuta, MD, Kiyohiko Hatake, MD PhD, Yasuhito Terui, MD PhD

Blood (2019) 134 (Supplement_1): 1498.

https://doi.org/10.1182/blood-2019-125096

Published: 2019

Journal Articles

Impact of Continuous and Maintenance Therapy on Survival Outcome in Patients with Newly Diagnosed Multiple Myeloma: A Multicenter Retrospective Collaborative Study of the Japanese Society of Myeloma

Shuji Ozaki, MD PhD, Hiroshi Handa, MD PhD, Takayuki Saitoh, MD PhD, Kazutaka Sunami, MD PhD, Tadao Ishida, MD PhD, Kenshi Suzuki, MD PhD, Tomoko Narita, MD, Shinsuke Iida, MD PhD, Yuichi Nakamura, MD PhD, Kazuhito Suzuki, MD, Noriko Nishimura, MD PhD, Hirokazu Murakami, MD PhD, Kazuyuki Shimizu, MD

Blood (2019) 134 (Supplement_1): 3085.

https://doi.org/10.1182/blood-2019-125390

Published: 2019

Journal Articles

Cell-Free DNA Genotyping Analysis in Diffuse Large B-Cell Lymphoma; The Correlation between TP53 Gene Mutation and Cereblon Gene Mutation

Hideki Uryu, MD, Yuko Mishima, MD PhD, Yuji Mishima, PhD, Masahiro Yokoyama, MD, Noriko Nishimura, MD PhD, Yoshiharu Kusano, MD, Takashi Okabe, MD, Norihito Inoue, MD, Takanori Fukuta, MD, Yuko Shirouchi, MD, Kiyohiko Hatake, MD PhD, Yasuhito Terui, MD PhD

Blood (2019) 134 (Supplement_1): 2786.

https://doi.org/10.1182/blood-2019-122920

Published: 2019

Journal Articles

The Necessary for Long-Term Follow-up of Mutated Genes and Clonal Evolutions in Multiple Myeloma Combined with cfDNA Assay

Yuko Mishima, MD PhD, Yuji Mishima, PhD, Masahiro Yokoyama, MD, Noriko Nishimura, MD PhD, Yoshiharu Kusano, MD, Norihito Inoue, MD, Hideki Uryu, MD, Takanori Fukuta, MD, Yuko Shirouchi, MD, Kiyohiko Hatake, MD PhD, Yasuhito Terui, MD PhD

Blood (2019) 134 (Supplement_1): 5515.

https://doi.org/10.1182/blood-2019-122977

Published: 2019

Journal Articles

Impact of Creatinine Clearance in Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP : A Real-World Long-Term Observation Analysis at a Single Institute

Noriko Nishimura, MD PhD, Takanori Fukuta, MD, Anna Nishihara, MD, Yuko Shirouchi, MD, Hideki Uryu, MD, Norihito Inoue, MD, Yoshiharu Kusano, MD, Naoko Tsuyama, MD PhD, Kengo Takeuchi, MD PhD, Yuko Mishima, MD PhD, Masahiro Yokoyama, MD, Yasuhito Terui, MD PhD

Blood (2018) 132 (Supplement 1): 5399.

https://doi.org/10.1182/blood-2018-99-115897

Published: 2018

Journal Articles

The Prognostic Significance of Soluble Interleukin-2-Receptor, Beta-2-Microgrobulin and Serum Albumin in Patient with Diffuse Large B-Cell Lymphoma in the Rituximab Era

Norihito Inoue, MD, Masahiro Yokoyama, MD, Yuko Shirouchi, MD, Takanori Fukuta, MD, Anna Nishihara, MD, Yoshiharu Kusano, MD, Hideki Uryu, MD, Yuko Mishima, MD PhD, Noriko Nishimura, MD PhD, Naoko Tsuyama, MD PhD, Kengo Takeuchi, MD PhD, Yasuhito Terui, MD PhD

Blood (2018) 132 (Supplement 1): 4242.

https://doi.org/10.1182/blood-2018-99-115863

Published: 2018

Journal Articles

B-Symptoms, Performance Status and Response to First Therapy As Survival Predictive Factors for Peripheral T-Cell Lymphoma at Progression/Relapse: A Single Institute Analysis

Yuko Shirouchi, MD, Takanori Fukuta, MD, Anna Nishihara, MD, Norihito Inoue, MD, Hideki Uryu, MD, Yoshiharu Kusano, MD, Noriko Nishimura, MD PhD, Yuko Mishima, MD PhD, Masahiro Yokoyama, MD, Naoko Tsuyama, MD PhD, Kengo Takeuchi, MD PhD, Yasuhito Terui, MD PhD

Blood (2018) 132 (Supplement 1): 5360.

https://doi.org/10.1182/blood-2018-99-112038

Published: 2018

Journal Articles

The Prognosis of Transformed DLBCL Were Superior to De Novo DLBL after the Relapsed/Refractory Status Related to the MYC Translocation

Yuko Mishima, PhD, Masahiro Yokoyama, MD, Noriko Nishimura, MD PhD, Yoshiharu Kusano, MD, Hideki Uryu, MD, Norihito Inoue, MD, Anna Nishihara, MD, Takanori Fukuta, MD, Yuko Shirouchi, MD, Naoko Tsuyama, MD PhD, Kengo Takeuchi, MD PhD, Yasuhito Terui, MD PhD

Blood (2018) 132 (Supplement 1): 5417.

https://doi.org/10.1182/blood-2018-99-111081

Published: 2018

Journal Articles

Efficacy of Rituximab Maintenance for Diffuse Large B Cell Lymphoma with Transformation

Hideki Uryu, MD, Yuko Mishima, MD PhD, Masahiro Yokoyama, MD, Noriko Nishimura, MD PhD, Yoshiharu Kusano, MD, Norihito Inoue, MD, Anna Nishihara, MD, Takanori Fukuta, MD, Yuko Shirouchi, MD, Naoko Tsuyama, MD PhD, Kengo Takeuchi, MD PhD, Yasuhito Terui, MD PhD

Blood (2018) 132 (Supplement 1): 4229.

https://doi.org/10.1182/blood-2018-99-111513

Published: 2018

Journal Articles

The Role of Image Surveillance in Patients with Diffuse Large B-Cell Lymphoma: A Single-Center Validation Study

Takanori Fukuta, MD, Noriko Nishimura, MD PhD, Yuko Shirouchi, MD, Anna Nishihara, MD, Norihito Inoue, MD, Hideki Uryu, MD, Yoshiharu Kusano, MD, Yuko Mishima, MD PhD, Naoko Tsuyama, MD PhD, Kengo Takeuchi, MD PhD, Masahiro Yokoyama, MD, Yasuhito Terui, MD PhD

Blood (2018) 132 (Supplement 1): 2989.

https://doi.org/10.1182/blood-2018-99-113984

Published: 2018

Journal Articles

Poor Prognosis of CD5 Positive with Non Germinal Center Type of Diffuse Large B Cell Lymphoma Especially Having the Aberration of 19q13

Yuko Mishima, PhD, Yasuhito Terui, MD PhD, Masahiro Yokoyama, MD, Noriko Nishimura, MD PhD, Yoshiharu Kusano, MD, Yamauchi Hirofumi, MD, Norihito Inoue, MD, Anna Nishihara, MD, Naoko Tsuyama, MD PhD, Yuji Mishima, PhD, Kengo Takeuchi, MDPhD, Kiyohiko Hatake, MD PhD

Blood (2017) 130 (Supplement 1): 4153.

https://doi.org/10.1182/blood.V130.Suppl_1.4153.4153

Published: 2017

Journal Articles

Rituximab Combined Therapy and Maintenance Eliminate the Follicular Lymphoma with MYC Translocation

Anna Nishihara, MD, Yuko Mishima, PhD, Tomoko Takayama, Yasuhito Terui, MD PhD, Masahiro Yokoyama, MD, Noriko Nishimura, MD PhD, Yoshiharu Kusano, MD, Hirofumi Yamauchi, MD, Norihito Inoue, MD, Naoko Tsuyama, MD PhD, Yuji Mishima, PhD, Kengo Takeuchi, MDPhD, Kiyohiko Hatake, MD PhD

Blood (2017) 130 (Supplement 1): 2784.

https://doi.org/10.1182/blood.V130.Suppl_1.2784.2784

Published: 2017

Journal Articles

Acquired Chromosomal Abnormalities t(14;16), Del(17p) or Del(13q) after Receiving Chemotherapies Predict the Poor Prognosis of Multiple Myeloma

Hirofumi Yamauchi, MD, Yuko Mishima, PhD, Masahiro Yokoyama, MD, Noriko Nishimura, MD PhD, Yoshiharu Kusano, MD, Norihito Inoue, MD, Anna Nishihara, MD, Yasuhito Terui, MD PhD, Kiyohiko Hatake, MD PhD

Blood (2017) 130 (Supplement 1): 3116.

https://doi.org/10.1182/blood.V130.Suppl_1.3116.3116

Published: 2017

Journal Articles

Azacitidin Is Effective in the Therapy Related Myelodysplastic Syndrome.

Hirofumi Yamauchi, MD, Masahiro Yokoyama, MD, Yuko Mishima, MD PhD, Noriko Nishimura, MD PhD, Kyoko Ueda, MD, Yoshiharu Kusano, MD, Norihito Inoue, MD, Anna Takahashi, MD, Yasuhito Terui, MD PhD, Kiyohiko Hatake, MD PhD

Blood (2016) 128 (22): 5554.

https://doi.org/10.1182/blood.V128.22.5554.5554

Published: 2016

Journal Articles

Retrospective Analysis of NK/T Cell Lymphoma Prognostic Index (NKPI), EBV-DNA and Soluble IL-2 Receptor (sIL2R) for Extranodal NK/T-Cell Lymphoma, Nasal Type

Norihito Inoue, MD, Noriko Nishimura, MD PhD, Anna Takahashi, MD, Hirofumi Yamauchi, MD, Yoshiharu Kusano, MD, Kyoko Ueda, MD, Yuko Mishima, MD PhD, Masahiro Yokoyama, MD, Yasuhito Terui, MD PhD, Kiyohiko Hatake, MD PhD

Blood (2016) 128 (22): 5360.

https://doi.org/10.1182/blood.V128.22.5360.5360

Published: 2016

Journal Articles

The Prognosis of PR Patients after Induction Therapy Was Not Inferior to CR in ASCT-Eligible NDMM Patient.

Anna Takahashi, MD, Yuko Mishima, MD PhD, Norihito Inoue, MD, Yoshiharu Kusano, MD, Hirofumi Yamauchi, MD, Kyoko Ueda, MD, Noriko Nishimura, MD PhD, Masahiro Yokoyama, MD, Yasuhito Terui, MD PhD, Kiyohiko Hatake, MD PhD

Blood (2016) 128 (22): 5682.

https://doi.org/10.1182/blood.V128.22.5682.5682

Published: 2016

Journal Articles

Absolute CD4+ T-Cell Count Predicts Survival in Diffuse Large B-Cell Lymphoma

Yoshiharu Kusano, MD, Yasuhito Terui, MD PhD, Kengo Takeuchi, MD PhD, Anna Takahashi, MD, Norihito Inoue, MD, Hirohumi Yamauchi, MD, Naoko Tsuyama, MD, Kyoko Ueda, MD, Yuko Mishima, MD PhD, Noriko Nishimura, MD PhD, Masahiro Yokoyama, MD, Kiyohiko Hatake, MDPhD

Blood (2016) 128 (22): 3053.

https://doi.org/10.1182/blood.V128.22.3053.3053

Published: 2016

Journal Articles

The Relapsed - Memorial Sloan - Kettering Cancer Center (R-MSKCC) Prognostic Score Is a Risk-Stratification Model for the Central Nervous System (CNS) Involvement at Relapse in Patients with Diffuse Large B Cell Lymphoma (DLBCL) in the Rituximab Era

Noriko Nishimura, MD PhD, Yasuhito Terui, MD PhD, Kengo Takeuchi, MD PhD, Naoko Tsuyama, MD, Anna Takahashi, MD, Norihito Inoue, MD, Hirofumi Yamauchi, MD, Yoshiharu Kusano, MD, Yuko Mishima, MD PhD, Masahiro Yokoyama, MD, Kiyohiko Hatake, MD PhD

Blood (2016) 128 (22): 4221.

https://doi.org/10.1182/blood.V128.22.4221.4221

Published: 2016

Journal Articles

R-CHOP Therapy Cannot Overcome CD5 Positive Non-GCB Subtype of DLBCL

Yuko Mishima, MD PhD, Masahiro Yokoyama, MD, Noriko Nishimura, MD PhD, Kyoko Ueda, MD, Tadahiro Gunji, MD, Hideaki Nitta, MD PhD, Yoshiharu Kusano, MD, Norihito Inoue, MD, Anna Takahashi, MD, Naoko Tsuyama, MD, Kengo Takeuchi, MDPhD, Yasuhito Terui, MD PhD, Kiyohiko Hatake, MD PhD

Blood (2015) 126 (23): 1507.

https://doi.org/10.1182/blood.V126.23.1507.1507

Published: 2015

Journal Articles

The Presence of M Protein Is Strongly Associated with Very Poor Prognosis in Patients with Extranodal Diffuse Large B-Cell Lymphoma

Hideaki Nitta, MD PhD, Yasuhito Terui, MD PhD, Masahiro Yokoyama, MD, Yuko Mishima, MD PhD, Noriko Nishimura, MD PhD, Kyoko Ueda, MD, Tadahiro Gunji, MD, Yoshiharu Kusano, MD, Norihito Inoue, MD, Anna Takahashi, MD, Naoko Tsuyama, MD, Kengo Takeuchi, MD PhD, Kiyohiko Hatake, MD PhD

Blood (2015) 126 (23): 5638.

https://doi.org/10.1182/blood.V126.23.5638.5638

Published: 2015

NARROW

Serum Cell-Free DNA Concentration Is Predictive of Survival Outcomes and Its Genetic Mutation Analysis May Be Viable in Obtaining Pathological Information

Impact of Continuous and Maintenance Therapy on Survival Outcome in Patients with Newly Diagnosed Multiple Myeloma: A Multicenter Retrospective Collaborative Study of the Japanese Society of Myeloma

Cell-Free DNA Genotyping Analysis in Diffuse Large B-Cell Lymphoma; The Correlation between TP53 Gene Mutation and Cereblon Gene Mutation

The Necessary for Long-Term Follow-up of Mutated Genes and Clonal Evolutions in Multiple Myeloma Combined with cfDNA Assay

Impact of Creatinine Clearance in Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP : A Real-World Long-Term Observation Analysis at a Single Institute

The Prognostic Significance of Soluble Interleukin-2-Receptor, Beta-2-Microgrobulin and Serum Albumin in Patient with Diffuse Large B-Cell Lymphoma in the Rituximab Era

B-Symptoms, Performance Status and Response to First Therapy As Survival Predictive Factors for Peripheral T-Cell Lymphoma at Progression/Relapse: A Single Institute Analysis

The Prognosis of Transformed DLBCL Were Superior to De Novo DLBL after the Relapsed/Refractory Status Related to the MYC Translocation

Efficacy of Rituximab Maintenance for Diffuse Large B Cell Lymphoma with Transformation

The Role of Image Surveillance in Patients with Diffuse Large B-Cell Lymphoma: A Single-Center Validation Study

Poor Prognosis of CD5 Positive with Non Germinal Center Type of Diffuse Large B Cell Lymphoma Especially Having the Aberration of 19q13

Rituximab Combined Therapy and Maintenance Eliminate the Follicular Lymphoma with MYC Translocation

Acquired Chromosomal Abnormalities t(14;16), Del(17p) or Del(13q) after Receiving Chemotherapies Predict the Poor Prognosis of Multiple Myeloma

Azacitidin Is Effective in the Therapy Related Myelodysplastic Syndrome.

Retrospective Analysis of NK/T Cell Lymphoma Prognostic Index (NKPI), EBV-DNA and Soluble IL-2 Receptor (sIL2R) for Extranodal NK/T-Cell Lymphoma, Nasal Type

The Prognosis of PR Patients after Induction Therapy Was Not Inferior to CR in ASCT-Eligible NDMM Patient.

Absolute CD4+ T-Cell Count Predicts Survival in Diffuse Large B-Cell Lymphoma

The Relapsed - Memorial Sloan - Kettering Cancer Center (R-MSKCC) Prognostic Score Is a Risk-Stratification Model for the Central Nervous System (CNS) Involvement at Relapse in Patients with Diffuse Large B Cell Lymphoma (DLBCL) in the Rituximab Era

R-CHOP Therapy Cannot Overcome CD5 Positive Non-GCB Subtype of DLBCL

The Presence of M Protein Is Strongly Associated with Very Poor Prognosis in Patients with Extranodal Diffuse Large B-Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only